Stockholm – March 31, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the number of shares and votes in Oncopeptides has changed as a result of the rights issue which ended on March 16, 2026.
After the rights issue, the total number of shares in Oncopeptides amounts to 395,287,003 shares, of which 381,148,118 are ordinary shares and 14,138,885 are class C shares. After the rights issue, the total number of votes in Oncopeptides amounts to 382,562,006.5. The share capital has increased by SEK 13,620,072.330911 from SEK 30,300,707.563894 to SEK 43,920,779.894805.